<?xml version="1.0" encoding="UTF-8"?>
<ref id="pone.0229239.ref020">
 <label>20</label>
 <mixed-citation publication-type="journal">
  <name>
   <surname>Forns</surname>
   <given-names>X</given-names>
  </name>, 
  <name>
   <surname>Lee</surname>
   <given-names>SS</given-names>
  </name>, 
  <name>
   <surname>Valdes</surname>
   <given-names>J</given-names>
  </name>, 
  <name>
   <surname>Lens</surname>
   <given-names>S</given-names>
  </name>, 
  <name>
   <surname>Ghalib</surname>
   <given-names>R</given-names>
  </name>, 
  <name>
   <surname>Aguilar</surname>
   <given-names>H</given-names>
  </name>, 
  <etal>et al</etal>
  <article-title>Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial</article-title>. 
  <source>Lancet Infect Dis</source>. 
  <year>2017</year>
  <month>10</month>;
  <volume>17</volume>(
  <issue>10</issue>):
  <fpage>1062</fpage>â€“
  <lpage>8</lpage>. 
  <pub-id pub-id-type="doi">10.1016/S1473-3099(17)30496-6</pub-id>
  <?supplied-pmid 28818546?>
  <pub-id pub-id-type="pmid">28818546</pub-id>
 </mixed-citation>
</ref>
